These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1088 related items for PubMed ID: 26996778

  • 1. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
    Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, Eriksson J, Lubberink M, Almkvist O, Wall A, Antoni G, Nordberg A.
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
    [Abstract] [Full Text] [Related]

  • 2. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, Leuzy A, Almkvist O, Savitcheva I, Jonasson M, Lubberink M, Wall A, Antoni G, Nordberg A.
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [Abstract] [Full Text] [Related]

  • 3. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer's disease.
    Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Wall A, Nordberg A.
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
    [Abstract] [Full Text] [Related]

  • 4. Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease.
    Saint-Aubert L, Almkvist O, Chiotis K, Almeida R, Wall A, Nordberg A.
    Alzheimers Res Ther; 2016 Sep 29; 8(1):38. PubMed ID: 27683159
    [Abstract] [Full Text] [Related]

  • 5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2016 May 29; 139(Pt 5):1551-67. PubMed ID: 26962052
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF, Banzo I, De Arcocha-Torres M, Quirce R, Martínez-Rodríguez I, Lavado-Pérez C, Bravo-Ferrer Z, Rodríguez-Rodríguez E, Sánchez-Juan P, Carril JM.
    Nucl Med Commun; 2016 Nov 29; 37(11):1189-96. PubMed ID: 27341411
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease.
    Leuzy A, Rodriguez-Vieitez E, Saint-Aubert L, Chiotis K, Almkvist O, Savitcheva I, Jonasson M, Lubberink M, Wall A, Antoni G, Nordberg A.
    Alzheimers Dement; 2018 May 29; 14(5):652-663. PubMed ID: 29268078
    [Abstract] [Full Text] [Related]

  • 8. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD.
    Neuroimage Clin; 2014 May 29; 4():508-16. PubMed ID: 24818077
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.
    Eur J Nucl Med Mol Imaging; 2016 Jul 29; 43(7):1304-14. PubMed ID: 27003417
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL.
    Brain; 2014 Jun 29; 137(Pt 6):1762-71. PubMed ID: 24681664
    [Abstract] [Full Text] [Related]

  • 13. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.
    Neuroimage; 2010 Aug 15; 52(2):488-96. PubMed ID: 20385246
    [Abstract] [Full Text] [Related]

  • 14. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L, Hellwig S, Bormann T, Spehl TS, Buchert R, Meyer PT.
    Eur J Nucl Med Mol Imaging; 2018 Jul 15; 45(8):1442-1448. PubMed ID: 29546632
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A.
    J Nucl Med; 2012 Jan 15; 53(1):37-46. PubMed ID: 22213821
    [Abstract] [Full Text] [Related]

  • 20. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.
    Brain; 2006 Nov 15; 129(Pt 11):2856-66. PubMed ID: 16854944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.